Publications by authors named "N Franchimont"

Claim this Profile
S
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
Peter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, Robert T Naismith, Robert J Fox, Nathalie Franchimont

Mult Scler· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines.
Richard Furie, Victoria P Werth, Eric Milliman, Kyle Ferber, Roland Brown, Nathalie Franchimont

Arthritis Rheumatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary.
Richard A Furie, Ronald F van Vollenhoven, Kenneth Kalunian, Sandra Navarra, Juanita Romero-Diaz, Nathalie Franchimont

Immunotherapy· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.
Victoria P Werth, Richard A Furie, Juanita Romero-Diaz, Sandra Navarra, Kenneth Kalunian, Nathalie Franchimont

Immunotherapy· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis.
Orhan Aktas, Focke Ziemssen, Tjalf Ziemssen, Alexander Klistorner, Helmut Butzkueven, Nathalie Franchimont

Mult Scler Relat Disord· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis